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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is a common malignancy with dismal prognosis. Metastatic
spread and therapeutic resistance, the main causes of PDAC-related mortalities, are both partially underlined by the
epithelial-mesenchymal transition (EMT) of PDAC cells. While the role of Warburg metabolism has been recognized
in supporting rapid cellular growth and proliferation in many cancer types, less is known about the metabolic changes
occurring during EMT, particularly in the context of PDAC.
Results: In the current study, experimental models of EMT were established in the Panc-1 cell line of human PDAC via
exposure to two physiologically relevant EMT inducers (tumor necrosis factor-α and transforming growth factor-β)
and the metabolic consequences examined. The two EMT models displayed similar alterations in the general
metabolic profile including augmented glucose uptake and lactate secretion as well as the lack of change in
oxidative metabolism. Examination of molecular markers revealed differences in the pathways underlying the
metabolic rewiring. 13C-Glucose tracer data confirmed that a major portion of accumulated lactate was
derived from glucose, but subsequent flux analysis suggested involvement of non-canonical pathways
towards lactate production.
Conclusions: Our results characterize the metabolic reprogramming occurring during PDAC cell EMT and
highlight the common changes of increased glucose uptake and lactate secretion under different EMT
conditions. Such insight is urgently required for designing metabolic strategies to selectively target cells
undergoing EMT in PDAC.
Keywords: Epithelial-mesenchymal transition, Tumor metabolism, Pancreatic adenocarcinoma, Glucose
metabolism, 13C Metabolomics
Background
With a 5-year survival rate of less than 5 %, pancreatic
ductal adenocarcinoma (PDAC) is the most lethal com-
mon malignancy facing human society [1]. Surgical resec-
tion provides the only chance of cure, but most patients
are diagnosed at an advanced stage where local invasion
or distant metastasis has occurred [2, 3]. The inability to
undergo surgical resection and therapeutic resistance to
currently available chemotherapies together contributes
to pancreatic cancer’s poor prognosis [2, 4].
The propensity for both metastasis and therapeutic re-
sistance in tumors has been proposed to be associated
with the epithelial-mesenchymal transition (EMT) [5].
EMT is a trans-differentiation process active in embryo-
genesis and tissue repair where epithelial cells acquire
the phenotype and gene expression patterns of mesen-
chymal cells [5]. In the context of tumor development,
pathological EMT occurs when neoplastic cells of epi-
thelial origin transiently switch to a mesenchymal-like
phenotype in order to gain increased mobility, invasiveness,
* Correspondence: n.turner@unsw.edu.au
1Department of Pharmacology, School of Medical Sciences, University of
New South Wales, Sydney, NSW, Australia
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Liu et al. Cancer & Metabolism  (2016) 4:19 
DOI 10.1186/s40170-016-0160-x
stemness, and apoptotic resistance [6, 7]. Overexpres-
sion of EMT-inducing transcription factors Snail and
Slug have been reported in human PDAC samples and
cell lines [8]. Disseminated cells from early-stage PDAC
tumors were also found to express higher levels of
mesenchymal markers and EMT-inducing transcription
factors, paired with enhanced survival and self-renewal
properties, compared to the bulk of cells in the primary
tumor site [9]. Furthermore, pancreatic cancer cells that
survive after gemcitabine treatment, the frontline che-
motherapeutic intervention, tend to acquire EMT-like
phenotypes [10–12].
It is well-recognized that the development of tumors
requires not only the ability to proliferate uncontrollably,
but also altered metabolic programs to sustain the rapid
expansion [13–15]. While there are changes common
to multiple cancer types such as upregulated glucose
uptake and lactate production, known as the Warburg
effect, the metabolic profiles of individual tumors and
tumors at different stages of development also possess
unique features due to the heterogeneous nature of can-
cers. Studies in recent years have reported that PDAC
tumors take up increased amounts of glucose to fuel bio-
synthetic processes [16], display elevated glutaminolysis to
maintain redox balance [17] and scavenge fatty acids as
well as amino acids from extracellular space to synthesize
macromolecules such as lipids and proteins [18, 19].
These metabolic adaptations are the results of onco-
genic signaling active in PDAC and the tumor micro-
environment modulation, which collectively meet the
cell’s demand to accumulate biomass and proliferate.
EMT represents a series of major phenotypic alterations
and signals for a change in cellular demand from rapid
proliferation to survival and metastasis. It is therefore
plausible that cellular metabolism is reshaped to reflect
and support the new cell state. Indeed, research exploring
the possible metabolic reprogramming events associated
with EMT has emerged over the past 5 years describing
alterations of multiple metabolic enzymes involved in a
range of metabolic pathways upon EMT induction in
various cancer types [20–27]. Metabolic reprogramming
could also feedback into the EMT machinery as manipula-
tions of affected metabolic enzymes have partially blocked
or potentiated the induction of EMT [22, 23, 27]. Intri-
guingly, EMT-related metabolic changes reported in dif-
ferent cancer types appear to be disparate, highlighting
the plasticity and context dependency of cancer metabol-
ism. Considering the importance of EMT in underlying
PDAC-related mortalities, we investigated the metabolic
consequences of inducing EMT in a commonly used PDAC
cell line, Panc-1, with tumor necrosis factor-α (TNFα) and
transforming growth factor-β (TGFβ). Here, we report that
EMT states induced by both factors are accompanied
by increased glucose uptake and lactate secretion and




Recombinant human TNFα and TGFβ were purchased
from R&D Systems (Minneapolis, MN, USA). Antibodies
used are listed as follows: IkB, phospho-Smad2/3, total-
Smad2/3, Snail, vimentin, lactate dehydrogenase-A, fatty
acid synthase, stearoyl-CoA desaturase-1, phospho-acetyl-
CoA carboxylase, total-acetyl-CoA carboxylase (Cell signal-
ing, MA, USA); beta-actin, E-cadherin, N-cadherin (Santa
Cruz, TX, USA); hexokinase II, pyruvate kinase isoform
2, fructose-bisphophotase-2, total OXPHOS Human
WB Antibody Cocktail (Abcam, Cambridge, UK); Zeb1
(ProSci, CA, USA); and fructose-bisphophotase-1 (Abgent,
Wuxi, China). All other reagents were from Sigma-Aldrich
(MO, USA) unless stated otherwise.
Cell culture
Panc-1 cells from ATCC were cultured in Dulbecco’s
modified Eagle’s medium containing 4.5 g/L glucose
supplemented with 10 % fetal bovine serum and penicillin-
streptomycin. Panc-1 cells were treated with TNFα and
TGFβ at 40 and 10 ng/ml, respectively, for 72 h unless
otherwise specified.
Western blotting
Cells (1 × 106) growing on six-well plates were lysed in
RIPA buffer containing protease inhibitors as described
previously [28]. After denaturation, samples were resolved
by 10 % polyacrylamide gel electrophoresis (187 V, 1 h)
and transferred to PVDF membranes (65 V, 65 min). For
immunoblotting, membranes were blocked in 5 % skim
milk, incubated with primary antibodies overnight at 4 °C,
washed with Tris-buffered saline containing Tween 20
and incubated with secondary antibodies for an hour.
After washing, the membranes were developed with en-
hanced chemiluminescence reagents (Western Lighting
Plus-ECL, Perkin Elmer, MA, USA) and visualized under
Las4000 imager (GE Healthcare, WI, USA). Densitometry
was performed using ImageJ by obtaining the optical
density of each band.
Quantitative PCR
Total RNA was extracted using the Roche High Pure
RNA Extraction kit according to manufacturer’s in-
structions (Roche, Basel, Switzerland). RNA (1 μg) was
then reverse-transcribed using the Roche Transcriptor
first-strand cDNA synthesis kit. The resulting cDNA was
mixed with primers (primer sequences sourced from Sigma
KiCqstart or the Primer Bank [29], details in Additional file
1: Table S1) and SYBR-Green (Roche, Basel, Switzerland)
in 384- or 96-well plates. Quantitative PCR was performed
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using Roche 480 Light Cycler to obtain Ct values for
each gene of interest and a housekeeper beta-actin.
Analysis was conducted using the ΔΔCT method.
Wound healing assay
Panc-1 cells were seeded in a six-well plate and grown
to 50 % confluence over 2 days in the presence of TNFα,
TGFβ, or both. Scratch wounds were created by scraping
confluent cell monolayers with a sterile pipette tip on
three sites on each well. The cells were then incubated
under normal conditions with refreshed media containing
TNFα, TGFβ, or both under the Nikon Tie inverted time-
lapse microscope for 48 h. Migration at 24 and 48 h was
quantified by measuring the distance between two moving
borders of the cells from each scratch. Values from the
three wounds on each of the triplicate wells were aver-
aged, and three independent experiments were carried out
(Additional file 2: Figure S1).
Glucose uptake assay
Glucose uptake was assessed using the glucose analogue
2-deoxyglucose (2-DG) which is taken up into the cell
in the same manner as glucose but once phosphory-
lated cannot be further metabolized and is therefore
trapped in the cell. Cytochalasin B (25 μM) was applied
to a few wells for 15 min before the assay and during
the assay to give a measure of background glucose
uptake.
After washing with PBS, cells in six-well plates were in-
cubated in Ringer’s solution (140 mM NaCl, 20 mM
HEPES, 5 mM KCl, 2.5 mM MgSO4, 1.2 mM CaCl2,
pH 7.4) containing 10 μM 2-DG and 0.5 μCi/ml radio-
labelled 3H-2-DG for exactly 8 min. Following incubation,
cells were washed with cold PBS and lysed in 1 M NaOH.
The amount of 3H radioactivity in lysates was counted
using a beta-counter (Tri-Carb liquid scintillation counter,
Perkin Elmer, MA, USA) from which background was
subtracted. Protein concentrations of lysates were mea-
sured using BCA assay (Pierce BCA protein assay kit,
Thermo Fisher Scientific, MA, USA) for normalization.
Lactate assay
Lactate concentrations in cell culture media were deter-
mined in a reaction mixture containing hydrazine hydrate
(0.4 M, pH 9.0), EDTA (10 mM, pH 9.0), and NAD+
(0.5 mM). Samples and standards were added into 96-well
plates followed by lactate dehydrogenase (10 units/well),
and the amount of lactate was assessed by measuring the
amount of NADH formed at 340 nm after 2 h of incuba-
tion at 37 °C (a time point when lactate conversion is
complete).
Basal oxygen consumption
Cellular oxygen consumption was measured by the XF24
Analyzer (Seahorse Bioscience, MA, USA) following man-
ufacturer’s protocols. Cells were plated in five replicates in
24-well Seahorse assay plates and subjected to treatments
in growth media for 72 h. Prior to the assay, media was
changed to Seahorse assay media with the addition of
4.5 g/L glucose and 2 mM glutamine, pH 7.4. The basal
oxygen consumption was measured over 3 min for three
times with 1 min mixing in between the measurements.
Data were analyzed using the Seahorse software. Basal
oxygen consumption was normalized to protein concen-
tration determined by BCA method.
Glucose oxidation
Glucose oxidation was measured in cells seeded in six-well
plates (1 × 106 cells per well). Briefly, cells were washed
with PBS and incubated in DMEM containing 1 g/L D-
glucose and 2 μCi/ml 14C-glucose for 1 h at 37 °C.
After incubation, the culture media was added to 1 M
perchloric acid and the CO2 released was absorbed in
1 M NaOH solution over 2 h. The CO2 produced was
quantified by counting 14C content in the NaOH solu-
tion using a beta-counter (Tri-Carb liquid scintillation
counter, Perkin Elmer, MA, USA).
Lipid production from glucose
Cells from glucose oxidation experiments were collected
and snap-frozen to measure the amount of 14C incorpo-
rated into lipids over the duration of the assays. For total
lipid extraction, chloroform:methanol (volume ratio 2:1)
was added to the cells followed by 3 h of rotation at
room temperature. Sulfuric acid (2 M) was then added
to achieve phase separation, and the organic solvent layer
containing lipid was aspirated into a glass vial and dried
under nitrogen gas. The lipid was dissolved in ethanol and
its 14C content counted using a beta-counter and normal-
ized for protein concentration of the cell lysate.
13C-Glucose tracer experiments
Panc-1 cells were seeded in a six-well plate and grown
to 1 × 106 cells over 72 h in the presence of TNFα, TGFβ,
or both. To start the tracer experiment, culture media
were refreshed to glucose-free DMEM containing 4.5 g/L
[U-13C]-glucose (Sigma-Aldrich, Castle Hill, Australia)
and the respective cytokines. Fifty microliters of culture
medium was sampled at the start and at every hour for
5 h. Samples were placed on ice and then stored in a
−30 °C freezer until derivatization. Cell density by pro-
tein content was determined using three concurrent
cell culture replicates containing normal glucose.
Polar intracellular metabolites were harvested from
cells of the same tracer experiment at the fifth hour.
Briefly, cells were washed and quenched using ice-cold
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isotonic NaCl, then the metabolite were extracted using
5 ml of 50 vol.% methanol/water at −40 °C [30]. Polar
metabolites were retained by vortexing the extraction
mix with equal volume of chloroform and subsequently
discarding the organic phase. The aqueous phase was
dried by SpeedVac and then stored in a −30 °C freezer
until derivatization.
Calibration standards for glucose, lactate, and pyruvate
were prepared. With a starting concentration of 20 mM
glucose, 10 mM lactate, and 2 mM pyruvate, four sets of
standard concentrations were prepared by twofold serial di-
lution. Standards were stored in freezer until derivatization.
Metabolite sample preparation and GC-MS
Ten microliters of the thawed culture medium or cali-
bration standards was combined with 10 μl of succinic
acid-d6 (10 mM) in a glass vial and was evaporated to
dryness by SpeedVac. Dried samples were resuspended
in 15 μl of pyridine containing 20 mg/ml methoxyamine
HCl, and then incubated at 80 °C for 1 h. Fifteen micro-
liters of acetic anhydride was added, followed by another
hour of incubation at 80 °C. Once cooled to room
temperature, 50 μl of 1-butanol and 10 μl of ethyl
chloroformate were added in succession, with each step
followed by brief vortexing. Samples were kept at room
temperature for 5 min before being transferred into 600 μl
microcentrifuge tubes. Eighty microliters of chloroform
was added, followed by 10–15 mg of sodium hydrogen
carbonate solids and 75 μl of saturated sodium hydrogen
carbonate solution. The organic and aqueous phases
were mixed by pipetting. After the bubbling had ceased,
a further 150 μl of saturated sodium hydrogen carbonate
solution was added. After brief vortexing, samples were
centrifuged at 500g for 5 min. Approximately 70 μl of
the chloroform (bottom) phase was transferred into
GC-MS vials.
Dried intracellular metabolites were derivatized by silyla-
tion [31]. Fofty microliters of pyridine containing 20 mg/ml
methoxyamine HCl was added, followed by an hour of in-
cubation at 80 °C. Thirty microliters of MTBSTFA + 1 %
t-BDMCS was then added, followed by another hour of
incubation at 80 °C. Derivatized samples were then
transferred into GC-MS vials.
Derivatized metabolites were analyzed by GC-MS using a
HP-5ms capillary column (0.25 mm i.d. × 30 m× 0.25 μm;
Agilent J&W, Agilent Technologies, CA, USA) installed in
an Agilent HP 6890-5973 gas chromatography/mass
selective detector. The injection volume was 1 μL in
splitless mode with an inlet temperature of 250 °C. He-
lium flow was controlled at 1.1 ml/min. The MS was
operated in electron ionization mode at 70 eV. The
temperatures of the source, quadrupole, and the transfer
line were set at 150, 230, and 250 °C, respectively. For
extracellular metabolites, the GC temperature program
was set at 100 °C for 2 min, ramped at 15 °C/min to
150 °C and at 40 °C/min to 325, and finally held for
1.3 min. Ions for pyruvate (m/z 142–145), lactate (m/z
115–118), and glucose (m/z 314–318) were quantified
by selective ion monitoring mode. For intracellular
(silylated) metabolites, the GC temperature program
was set at 70 °C for 2 min, ramped at 4 °C/min to 200 °C
and at 15 °C/min to 290 °C, and finally held for 6 min.
Ions for pyruvate, lactate, and TCA cycle metabolites were
quantified by selective ion monitoring mode. GC-MS peak
integration and correction for natural isotope mass inter-
ference were performed using MATLAB scripts.
13C Flux analysis
A flux analysis approach was used to determine the propor-
tion and rate of lactate produced from glucose and from
non-glucose sources. A simplified glycolysis pathway was
used to map glucose carbons to pyruvate and lactate
(Fig. 4a). Non-glucose-derived carbon sources were assumed
to mix with the glucose carbons at the pyruvate node.
OpenFLUX was used to generate the metabolite and atom
balance models required for flux analysis (Additional file 3:
Figure S2) [32]. The non-stationary enrichment of extracel-
lular lactate and pyruvate was modelled by a forward Euler
method that described the accumulation dynamics of la-
belled lactate and pyruvate over time (Additional file 4).
Sensitivity analysis of estimated flux parameters was per-
formed using a Monte Carlo approach. Due to the lack of
enrichment data of glycolytic intermediates, intracellular iso-
topic steady-state was assumed.
Flux estimation was performed by constraint-based
least squares fitting of experimental data using MATLAB
R2012a (MathWorks, Natick, MA). This research includes
computations using the Linux computational cluster
Katana supported by the Faculty of Science, UNSW,
Australia.
Statistical analysis
All results are expressed as means ± standard error of the
mean (SEM). Results were analyzed by one-way ANOVA
with a Bonferroni post hoc test applied to compare every
treatment group to the control. Differences with p < 0.05
were deemed statistically significant.
Results
EMT was experimentally induced upon TNFα and TGFβ
treatments
To study the metabolic alterations associated with EMT in
PDAC, we first sought to establish models of experimen-
tally induced EMT in a human PDAC cell line. In vivo,
EMT is induced by a range of factors in the tumor micro-
environment among which TNFα and TGFβ have been
shown to induce EMT in multiple cancer types [33–37].
PDAC is known to have a dense stromal component
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containing myofibroblasts as well as infiltrating immune
cells, and a hyperactive TGFβ signaling in a subset of these
tumor cells [38, 39]. We therefore modelled EMT by
treating Panc-1 cells, a commonly used human PDAC cell
line harboring the prevalent KRAS mutation, with the
principal cytokine secreted by macrophages (TNFα), or
the stromal-derived growth factor TGFβ or a combination
of both factors.
While both TNFα and TGFβ can induce EMT [33, 40],
these two cytokines were reported to work through differ-
ent pathways [41, 42], which we initially sought to confirm
in the Panc-1 cell line. TNFα mainly signals through
the NFkB pathway, with IkB degradation indicative of
the activation of this pathway [41]. The canonical sig-
naling pathway of TGFβ, on the other hand, involves
Smad2/3 and 4. The phosphorylation of Smad2 or 3 en-
ables the formation of heterodimers with Smad4, which
translocate to the nucleus to regulate gene expression
[42]. The degradation of IkB and phosphorylation of
Smad2/3 were both seen clearly at the 0.25-h time
point (Fig. 1a), indicating the rapid activation of TNFα
and TGFβ pathways. The signaling events were sustained
for a number of hours before inhibitory signals overrode.
Snail is one of the major EMT-inducing transcription fac-
tors orchestrating the coordinated changes in gene expres-
sion during the transition [5]. Figure 1a showed that the
Snail level started to accumulate after 1 h of TGFβ treat-
ment, peaked at 24 h, and remained elevated up to 72 h.
Despite engaging different signaling pathways, at the
end of the 72-h incubation, morphological changes re-
sembling EMT was clearly observed in all treatment
groups, with cells becoming spindle-shaped and scattered
compared to cobble stone-shaped controls (Fig. 1b). Mo-
lecular characterization revealed that the protein level of
epithelial marker E-cadherin was reduced with all treat-
ments (p < 0.001), while those of mesenchymal markers
N-cadherin (p < 0.01 for the combined treatment) and
vimentin (p < 0.01 for all treatments) were increased
(Fig. 1c). The profound increase of Snail (encoded by
SNAI1) was seen at the protein and RNA levels when
TGFβ was added (Fig. 1c, d). For other prominent mem-
bers of the EMT-inducing transcription factor family, all
treatments resulted in upregulation of Zeb1 at the protein
level (p < 0.01) and Slug (encoded by SNAI2) was increased
by TGFβ at the transcript level, with a similar trend ob-
served for TNFα (Fig. 1c, e). The induction of EMT was
further confirmed by an increased migration of Panc-1 cells
following treatment for 48 h (Fig. 1f). Overall, robust EMT
in the Panc-1 cell line was induced by the addition of TNFα
and/or TGFβ to the culture media for up to 72 h.
Glycolysis is enhanced with TNFα- and TGFβ-induced EMT
Cancer cells are known to exhibit increased glycolytic
activity and lactate production compared to their normal
counterparts even in the presence of oxygen, a phe-
nomenon described as the Warburg effect. Changes in the
glycolytic pathways were therefore investigated upon EMT
induction in Panc-1 cells. TNFα, TGFβ, and a combination
of the two all led to a nearly twofold increase in glucose
uptake (Fig. 2a). The treatments also increased extracellu-
lar lactate concentrations, secreted by the cells over 3 days,
to varying extents (+33–60 %, P < 0.05) (Fig. 2b). Elevated
glucose uptake rates were accompanied by increased ex-
pression of glucose transporters with Glut1 increased by
TGFβ and Glut3 increased by TNFα (Fig. 2d, e). Levels
of glycolytic enzymes involved in glucose phosphoryl-
ation (hexokinase II (HK2)), pyruvate production (pyru-
vate kinase isoform 2 (PKM2)), lactate production (lactate
dehydrogenase A and B (LDH-A and LDH-B)), and secre-
tion (monocarboxylic acid transporter 1 and 4 (MCT1
and MCT4)) were also examined to elucidate possible
mechanisms of increased lactate production. While HK2
increased modestly in response to TNFα (40 %, p < 0.05),
LDH-A decreased slightly with TNFα treatment (22 %,
p < 0.05) and PKM2 increased with the combined treat-
ment (14 %, p < 0.01), the levels of other glycolytic en-
zymes remained the same (Fig. 2c, f–h). The expression of
the gluconeogenic enzyme fructose-1, 6-bisphosphotase 1
(FBP1) was reported to be repressed by Snail upon EMT
in breast cancer [21], but this was not observed in our
model (Fig. 2c). Surprisingly, the treatments resulted in
significant and variable changes in the different isoforms
of pyruvate dehydrogenase kinase (PDK 1–4) (Fig. 2i–l).
Overall, Panc-1 cells displayed enhanced glucose uptake
and lactate secretion upon EMT induction but showed no
major changes in the levels of glycolytic enzymes.
Oxidative metabolism was not changed upon TNFα- and
TGFβ-induced EMT
Following the observation of upregulated glycolysis, we
next examined the metabolic profiles of oxidative path-
ways. Basal oxygen consumption rate (OCR) was mea-
sured to give an overall indication of oxidative activity in
these cells and was found to be unchanged upon TNFα-
and TGFβ-induced EMT (Fig. 3a). The levels of protein
subunits of mitochondrial electron transport chain (ETC)
complexes I, II, and III also remained the same as control
(Fig. 3b). To assess the oxidation of glucose, radioactive
U-14C-glucose tracer was used, and similar to the overall
oxidative metabolism, no difference was observed in glu-
cose oxidation across the groups (Fig. 3c).
Endogenous lipid production from glucose is unchanged
upon TNFα- and TGFβ-induced EMT
Fast proliferating cells need to make membranes at a
sufficient rate so the endogenous production of lipids is
frequently upregulated in cancer cells [43]. When U-
14C-glucose tracer was made available to the cells, 14C
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incorporation into total lipids did not change with any of
the EMT treatments (Fig. 3d). Assessment of enzymes
involved in de novo lipid synthesis, however, revealed
reductions in both fatty acid synthase (FAS) and stearoyl-
CoA desaturase-1 (SCD1) protein levels with all three
treatments (Fig. 3e). The decrease in SCD1 following
exposure to TNFα alone was the most pronounced (p <
0.001) (Fig. 3e). Phospho-acetyl-CoA carboxylase (ACC)
(P-ACC, inactive) and total-acetyl-CoA carboxylase (T-
ACC) levels did not show differences between the groups
(Fig. 3e). Taken together, no difference in glucose-sourced
lipogenesis was observed in TNFα- and TGFβ-induced
EMT models despite some changes in lipogenic enzyme
levels.
13C-Glucose tracer showed increased glucose-to-lactate
conversion upon EMT induction
To confirm the changes in glycolysis and to provide a more
complete picture of metabolic alterations upon EMT in-
duction, 13C-glucose metabolomics experiments were
carried out. Cells were treated with the respective com-
pounds for 72 h with 13C-glucose replacing normal glu-
cose in the media for the last 5 h. Samples of culture
media were taken every hour for the last 5 h, and cells
were collected at the end.
Over the 5-h time course, Panc-1 cells that underwent
EMT in response to treatments showed greater rates of
extracellular lactate accumulation (Fig. 4b). Results were
consistent with the prior lactate assay (Fig. 2b), although
estimates were highest for Panc-1 cells treated with TGFβ
alone. For the accumulated amount of 13C-enriched lac-
tate (i.e., derived from glucose), TGFβ-treated cells showed
the greatest accumulation at 6.1 mM/mg protein, whereas
for control cells, it was at 3.6 mM/mg protein. For all con-
trol and treated cells at least 73 % of the lactate present
extracellularly was derived from glucose (Additional file 5:
Figure S3), confirming the dominant role of aerobic gly-
colysis in lactate production (Fig. 2).
The extracellular accumulation of enriched pyruvate
was also observed, but the quantities accumulated were
not different between the control and the treatments, and
the concentrations accumulated were less than lactate by
an order of magnitude (Additional file 5: Figure S3 ). The
amount of unlabeled pyruvate, already present in the
culture medium, decreased over time. This suggested the
simultaneously consumption and production of extracel-
lular pyruvate.
No appreciable changes in TCA cycle activity
The enrichment patterns of intracellular malate, aspar-
tate (proxy for oxaloacetate), α-ketoglutarate, and citrate
were similar between the control and the EMT-induced
cells (Fig. 4d). The approximately twofold increase in m0
fraction from citrate to α-ketoglutarate suggested significant
glutaminolysis driving TCA cycle fluxes. Nonetheless, the
extent of glutamine mixing with α-ketoglutarate remained
steady across all treatments and control.
The enrichment data also suggested that cells were sim-
ultaneously decarboxylating and carboxylating pyruvate.
Two-carbon acetyl-CoA, produced by pyruvate dehydro-
genase, was fully catabolized, as indicated by the m2 and
m4 fractions in citrate, and the propagation of these
fractions to malate and aspartate. A greater m3 fraction
in malate and aspartate compared to α-ketoglutarate sug-
gested some contribution of pyruvate carboxylase towards
the synthesis of oxaloacetate from pyruvate and a revers-
ible malate dehydrogenase. Overall, all three major path-
ways that feed into TCA cycle, namely glutaminolysis,
glycolysis, and anaplerotic flux, were actively engaged
to a similar extent between the control and the EMT-
induced cells.
Contribution of alternative pathways towards lactate
production
The detection of about 40 % m0 (unlabeled) fraction of
intracellular pyruvate and lactate indicated significant
conversion of non-glucose substrates to the pyruvate node.
The production of unlabeled (natural enrichment) lactate
was found to have increased in the EMT-induced cells
as well, from 0.3 mM/mg protein for the control to be-
tween 1.12 and 1.75 mM/mg protein for TNFα- and
TGFβ-treated cells (Additional file 5: Figure S3). The re-
sults raised the possibility that EMT may increase catabol-
ism of alternative substrates, such as amino acids, to
lactate.
It is possible that intracellular and extracellular pools
of lactate and pyruvate are exchanging reversibly (i.e.,
well-mixed), thus contributing to the observed dilution
(See figure on previous page.)
Fig. 1 EMT is induced upon TNFα and TGFβ treatments. Panc-1 cells were cultured in the presence of 40 ng/ml TNFα (α) or 10 ng/ml TGFβ (β)
or both (+) for 72 h. a Western blot detection of IkB, phospho-Smad2/3, total-Smad2/3, and Snail at 0, 0.25, 0.5, 1, 3, 24, 48, and 72 h time points.
β-actin was used as a loading control. b Cell morphology under bright-field microscopy at the end of incubation. c Western blot detection of
E-cadherin, N-cadherin, vimentin, and Snail. β-actin was used as a loading control. d, e Measurements of SNAI1 and SNAI2 mRNA levels by qPCR.
β-actin was used as a housekeeper. f Cells were seeded onto six-well plates and allowed to grow to 50 % confluence in the presence of added
factors for 2 days. The monolayer was wounded with a plastic tip and monitored under bright-field microscope for 48 h with continued treatments
with images taken at 0, 24, and 48 h. Cell migration was quantified by assessing percentage wound closure using the ImageJ software. Results are
shown as mean ± SEM with n = 3. *p<0.05, **p < 0.01, ***p < 0.001
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Fig. 2 Glycolysis was promoted upon TNFα- and TGFβ-induced EMT. Panc-1 cells were first cultured in the presence of 40 ng/ml TNFα or 10 ng/ml
TGFβ or both for 72 h to induce EMT. a Rate of glucose uptake was measured using the non-metabolisable glucose analogue 3H-2-deoxy-glucose
tracer over an 8-min period. The amount of 3H radiation trapped in the cells were counted using a beta-counter. b Lactate assay was performed on
cell culture media collected after 72 h from the respective groups. c Western blot detection of hexokinase II (HK2), fructose-1,6-bisphosphotase1 (FBP1),
fructose-1,6-bisphosphotase 2 (FBP2), pyruvate kinase isoform 2 (PKM2) and lactate dehydrogenase-A (LDH-A). β-actin was used as a loading control.
d-l qPCR measurements of SLC2A1 (encoding Glut1), SLC2A3 (encoding Glut3), lactate dehydrogenase B (LDH-B), monocarboxylate transporter 1,
(MCT1), monocarboxylate transporter 4 (MCT4) and pyruvate dehydrogenase kinase 1-4 (PDK 1-4) transcripts using β-actin as a housekeeper. Results
are shown as mean ± SEM with n = 5 (a) or n = 3 (b-l). *p < 0.05, **p < 0.01, ***p < 0.001
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effect. A tracer model was thus constructed to estimate
the contribution of glucose and unlabeled substrates to
pyruvate and lactate and, at the same time, subtracting
the effects of reversible pyruvate and lactate exchange
(Fig. 4a). Flux analysis was then used to calculate the
contribution of non-glucose-derived substrates to the
pyruvate note using the enrichment and abundance of
extracellular lactate and pyruvate as constraints.
Flux results suggested that TNFα-treated cells, alone
or in combination with TGFβ, showed an increased
conversion of unlabeled substrates to pyruvate, with
approximately the same increments propagated to the
respective net lactate secretion rates (Fig. 4b). For cells
treated with TGFβ alone, however, model results indicated
that the high lactate production might be achieved by sup-
pressing downstream pathways that consumed pyruvate,
rather than by increasing conversion rates of glucose and
unlabeled substrates. Slight downward shifts among the
fluxes of pyruvate dehydrogenase (Fig. 4c) and TCA cycle
enzymes, albeit not significant, were observed for the
TGFβ-treated cells.
Additionally, the absence of m1 and m2 fractions of pyru-
vate and lactate (Fig. 4d)—intracellular and extracellular—
strongly suggested the lack of NADP-dependent malic
enzyme (ME1) to convert partially labelled TCA cycle
intermediates into cytoplasmic pyruvate. Indeed, flux
activity using the intracellular enrichment verified the
lack of connectivity between TCA cycle metabolites
and cytoplasmic pyruvate (Fig. 4c).
Overall, the tracer data appear to suggest that lactate
production in EMT-induced cells, while predominantly
attributed to glucose, also involve catabolism of alterna-
tive substrates independent of the TCA cycle.
Discussion
Cancer cells with EMT features are observed under
various experimental settings and clinical situations. In
recent years, several studies have been conducted inves-
tigating the metabolic changes during EMT in breast,
lung, and ovarian cancers, following an increased rec-
ognition of metabolic reprogramming as a hallmark of
tumor development [20–27]. In view of the important
role EMT plays in PDAC metastasis and chemoresis-
tance, we sought to understand the metabolic adapta-
tions underlying PDAC EMT. Here, we showed that
exposure to TNFα and TGFβ, two factors commonly
present in the tumor microenvironment that signal
through distinct pathways, induced overt EMT in the
Panc-1 cell line of human PDAC, reflected by EMT-like
morphological, molecular, and functional changes. The
induction of EMT by both of these factors was
Fig. 3 Oxidative metabolism is with TNFα- and TGFβ-induced EMT. Panc-1 cells were cultured in the presence of 40 ng/ml TNFα or 10 ng/ml TGFβ
or both for 72 h to induce EMT. a Oxygen consumption rate (OCR) was measured using the Seahorse XF24 Bioanalyzer at basal conditions. b Western
blot detection of mitochondrial electron transport chain complex III, II, and I. β-actin was used as a loading control. c Glucose oxidation was measured
using the U-14C-glucose tracer over a 1-h period. The amount of 14C in CO2 originated from
14C-glucose was counted using a beta counter to give an
indication of glucose oxidation rate. d Total lipid in the cells was extracted using the chloroform/methanol method following 1 h incubation
in U-14C-glucose-containing media. The amount of 14C incorporated in the total lipid was quantified using a beta counter. e Western blot
detection of fatty acid synthase (FAS), phospho- and total-acetyl-CoA carboxylase (P-ACC and T-ACC), and stearoyl-CoA desaturase-1 (SCD1).
β-actin was used as a loading control. Results are shown as mean ± SEM with n = 5 (a) or n = 3 (b, e) or n = 4 (c, d). *p < 0.05, **p < 0.01, ***p < 0.001
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accompanied by augmentations of glucose uptake and
lactate secretion, while no major changes to oxidative me-
tabolism were observed. In addition, 13C-glucose metabo-
lomics combined with flux analysis revealed that the
increase in lactate production by these two treatments
might be achieved via different mechanisms and suggested
possible contributions of nutrients other than glucose.
While there is relatively limited literature in this area,
the nature of the metabolic alterations appears to vary
widely across different cancer types and EMT models.
One of the earliest studies reported findings similar to
our current results, with increased Glut1 expression
and glucose uptake in the breast cancer cell line MCF-7
undergoing TGFβ-induced EMT [20]. The downregula-
tion of gluconeogenic enzyme FBP1 was described as a
predominant EMT-related change by Dong et al. [21],
on the basis of comparison of luminal and the more meta-
static basal subtype of breast cancer. The enhancement of
glycolysis and reduction in gluconeogenesis were also
observed in two breast cancer cell lines exhibiting EMT
features after mammosphere cultures by Kondaveeti and
colleagues, who also noted decreases in enzymes involved
in the pentose phosphate and hexosamine synthesis
pathways [26]. In contrast, three KRAS- or EGFR-driven
non-small cell lung cancer (NSCLC) cell lines treated with
TGFβ or erlotinib to induce EMT displayed reduced gly-
colysis to oxidation ratio and lower PDK4 expression [23].
Increased oxygen consumption rate and coordinated sup-
pression of lipogenesis were reported in a separate study
on a TGFβ-induced EMT model in NSCLC [27]. Surpris-
ingly, increased expression of GLUT3 transporter was also
associated with TGFβ treatment in the same cancer type
[24]. In ovarian cancer, Aspuria et al. induced EMT via
succinate dehydrogenase B knockdown and saw decreased
maximal OCR, accompanied by increased glucose con-
tribution to pentose phosphate pathway and nucleotide
synthesis [22].
Physiologically, the induction of EMT is the result of
contextual cues originating from surrounding cells and
the circulation acting upon cancer cells that are sensitized
Fig. 4 [U-13C]-Glucose tracer model data and flux results. Panc-1 cells were cultured in the presence of 40 ng/ml TNFα or 10 ng/ml TGFβ or both
for 72 h prior to the start of the labelling experiment. a Metabolic model used for fitting of the extracellular enrichment data, allowing for the
reversible exchange of pyruvate and lactate. G6P glucose 6-phosphate, G3P glyceraldehyde 3-phosphate. b Estimated rates of lactate production and
uptake of non-glucose substrates from extracellular enrichment data. c Estimated yields of pyruvate dehydrogenase (PDH) and NADP-dependent malic
enzyme (ME1) from intracellular enrichment data. Box-and-whisker plots show the 2.5th, 25th, 50th, 75th, and 97.5th percentile values; optimum
values shown as asterisks. d Enrichment fractions of intracellular metabolites pyruvate (PYR), lactate (LAC), alanine (ALA), malate (MAL), aspartate (ASP),
α-ketoglutarate (AKG), and citrate (CIT) showing the fractions of carbon atoms of these metabolites derived from glucose
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by oncogenic mutations. Therefore, the diversity of the
tumor microenvironment and genetic composition could
partially underscore the heterogeneity of EMT responses.
In this context, it is worth noting however that within the
same cancer type, there is no current evidence that the
status of common mutations appears to have a major
impact on EMT-related metabolic reprogramming, as
NSCLC cell lines harboring mutant or wild-type KRAS,
EGFR, and TP53, as well as breast cancer cell lines
with or without HER2 overexpression do not display
mutation-specific changes [23, 26]. Given the complexity
of genetic events in cancers, further comprehensive studies
are needed to uncover any possible interactions between
genomic and metabolic landscapes in relation to EMT.
The disparity of EMT metabolic reprogramming in
different contexts could additionally be related to varia-
tions in the accompanying phenotypic transformations,
which are potentially linked to differential metabolic
modulations. For instance, stem cells exhibit heightened
rates of glycolysis [44, 45] and inhibition of glycolysis was
reported to suppress stemness features in glioblastoma
stem-like cells [46]. Hence, the increased glycolytic flux
observed in some EMT models may be related to the
stemness conferred by EMT. Increases in glucose uptake
would presumably promote cell survival under hypoxic
and nutrient poor conditions, while the lactate secreted
could facilitate matrix degradation [47] and evasion of
immune surveillance [48, 49], echoing the promotion of
apoptotic resistance and invasiveness by EMT. On the
other hand, elevated mitochondrial biogenesis and oxida-
tive phosphorylation have, in some cases, been associated
with chemoresistance and metastatic behaviors which are
also promoted by EMT [50–52].
One prominent feature of PDAC is the presence of
dense stromal compartment surrounding the tumors.
The dense stroma both constraints the delivery of oxy-
gen/nutrients to the tumor cells and can also act as a
physical barrier for extravasation. For PDAC cells that
have undergone EMT, the increased lactate excretion
may be essential for traversing the stromal layer before
reaching the circulation and maintaining viability
along the way. Recent reports by Fisher et al. [53]
and Zheng et al. [54] questioned the role of EMT in
cancer metastasis but provided in vivo evidence that
EMT cells are resistant to chemotherapy. It is known
that after chemotherapy or experimental induction of
gemcitabine resistance, a proportion of PDAC cells exhibit
EMT features and display signature stem cell surface
markers [12, 55]. Treatment with the anti-glycolytic agent
3-bromopyruvate sensitized primary PDAC cancer stem
cells to gemcitabine [56]. The metabolic alterations seen
in PDAC cells in the present study are consistent with an
increase in stem-like properties with EMT, which could
contribute to chemoresistance.
Pinpointing the molecular changes underlying the ob-
served metabolic reprogramming with EMT is important
for developing targeted therapies. It could be reasoned
that increased lactate output was driven by increased ex-
pression of GLUT transporters (1 and 3) and the conse-
quent increase in glycolytic influx, as no major changes
in glycolytic and lactate-producing enzymes were ob-
served. However, 13C enrichment data suggested that lac-
tate was simultaneously produced from both glucose and
non-glucose sources, albeit the former contributing to the
majority. While glutamine could act as a significant non-
glucose substrate for cancer cells, data from radioactive
and stable tracer experiments revealed that neither the
TCA cycle activity was enhanced nor its intermediates
contributed to lactate production. Further research will
therefore be needed to identify the full spectrum of lactate
precursors in the EMT models when strategies to “starve”
the malignant cells are pursued. In addition, enrichment
data from TGFβ-treated cells raised the prospect that a
greater pyruvate-to-lactate conversion during EMT could
also be achieved by downregulating pyruvate consumption
pathways, e.g., PDH. The observed changes of PDK iso-
forms, which control the partitioning of pyruvate to the
TCA cycle, were disparate, possibly providing a mechan-
ism of fine tuning glucose metabolism.
Conclusions
Our study has revealed increases in glucose uptake and
lactate secretion as prominent metabolic adaptations of
two models of EMT in a human PDAC cell line. Under-
standing of the metabolic reprogramming associated with
EMT in PDAC provides evidence for developing meta-
bolic strategies to selectively target EMTcells and to avoid
the accidental promotion of EMT in cancer cell popula-
tions while applying metabolic therapies against proliferat-
ing cells. The differences in the underlying molecular
changes seen in the two EMT models in the current study
and other EMT models in various cancer types further
highlight the heterogeneity of cancers and therefore a need
for context-specific investigations of tumor metabolism.
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